Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

1.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K
Drug Regulation01:25

Drug Regulation

2.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.0K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

270
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
270
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.1K
Drug Discovery: Overview01:26

Drug Discovery: Overview

9.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual-driven by regulatory science and policy reconstruction: Traditional Chinese medicine (TCM) new drugs accelerate development-A critical review of highlights in registration and regulation of TCM and natural medicine new drugs in China (2021-2025).

Acta pharmaceutica Sinica. B·2026
Same author

The optimal blood pressure target in old and very old patients with hypertension.

Age and ageing·2026
Same author

Optimal blood pressure target in patients with uncomplicated hypertension: a target trial emulation study.

Nature communications·2026
Same author

Overcoming the HIV Pre-Exposure Prophylaxis Uptake Barrier With A Health Action Process Approach and Conditional Economic Incentives Among Men Who Have Sex With Men in 3 Chinese Cities: Protocol for a Randomized Controlled Trial.

JMIR research protocols·2026
Same author

Risk of severe cardiovascular events and incidence rate of cardiopulmonary events among patients with COPD in China: a retrospective cohort study.

BMJ open·2026
Same author

Novel inflammatory markers for predicting adverse pregnancy outcomes in pregnant women with polycystic ovary syndrome: a retrospective case‒control study.

BMC pregnancy and childbirth·2026

Related Experiment Video

Updated: Oct 3, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

682

Pharmacovigilance in China: Evolution and future challenges.

Haibo Song1,2, Xiaojing Pei3, Zuoxiang Liu4

  • 1National Center for ADR Monitoring, Beijing, China.

British Journal of Clinical Pharmacology
|February 15, 2022
PubMed
Summary

China

Keywords:
Chinacurrent situationperspectivepharmacovigilance

More Related Videos

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
05:59

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

Published on: November 4, 2022

1.9K
Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method
09:16

Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method

Published on: May 12, 2023

1.3K

Related Experiment Videos

Last Updated: Oct 3, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

682
An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
05:59

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

Published on: November 4, 2022

1.9K
Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method
09:16

Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method

Published on: May 12, 2023

1.3K

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Regulatory Science
  • Public Health

Background:

  • Drug-related adverse reactions pose significant global health risks.
  • Effective pharmacovigilance systems are crucial for mitigating these risks.
  • China formally implemented its national pharmacovigilance system in 2019 to enhance medication safety.

Purpose of the Study:

  • To analyze the implementation status and challenges of China's pharmacovigilance system.
  • To identify areas for improvement in drug safety monitoring and regulation.
  • To explore strategies for enhancing pharmacovigilance capabilities in China.

Main Methods:

  • Analysis of China's spontaneous adverse drug reaction reporting system.
  • Review of regulatory documents and government initiatives.
  • Assessment of challenges faced by marketing authorization holders and medical education.

Main Results:

  • China's spontaneous reporting system requires enhancement for regulatory decision-making.
  • Marketing authorization holders need to strengthen their pharmacovigilance responsibilities.
  • Gaps exist in professional pharmacovigilance education within Chinese medical schools.

Conclusions:

  • China is actively working to improve its pharmacovigilance system through action plans and new surveillance methods.
  • Strengthening professional capacity and stakeholder collaboration is key to advancing drug safety.
  • Initiatives like patient-based reporting and active surveillance aim to align China's practice with international standards.